SEQTOR-Study

Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs

II

Status: Rekrutierung beendet

Zeitraum

2014

2018

Zentren

Keine Zentren gesucht

Patienten

180

108

14.04.2022

Beteiligte

AIO-Arbeitsgruppen

Identifier

AIO-NET-0215/ass

Kontakt

Leitung

Prof. Dr. Marianne Pavel

Ansprechpartner*in

Prof. Dr. Marianne Pavel
Telefon +49 30 450553022
E-Mail marianne.pavel@charite.de